Ionis Pharma (IONS) Reports Q2 Loss of $0.09/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ionis Pharmaceuticals (IONS) PT Raised to $50 at Stifel; Reiterates Hold
August 9, 2017 7:08 AM EDTStifel raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $50.00 (from $42.00) while maintaining a Hold rating following the company's 2Q. IONS reported a net loss of $(0.09)/share, narrowly missing Consensus estimates for $(0.11). Higher-than-estimated revenues of $105M drove most of the beat,... More
